3 minute read
Jan. 14, 2024

Gadopiclenol: Reducing Gadolinium Retention Risks Through Coordination Chemistry

Drug Hunter Team

While gadolinium-based MRI contrast agents (GBCAs) are important for enhancing MRI and MRA imaging, several studies have shown that gadolinium can be retained in the brain and body for months to years after GBCA injection, prompting the FDA to issue box warnings to the drug class. Gadopiclenol, the ninth approved GBCA, was designed to enable use of a lower gadolinium dose than other agents. This highlight reviews how it works and why it’s notable.



Other articles you may be interested in